Core Viewpoint - The article discusses the gender differences in the usage of GLP-1 medications for weight loss, highlighting that women are more likely to consider these drugs earlier than men, who tend to prefer diet and exercise for weight management [4][5][6]. Group 1: Gender Differences in Usage - Women account for a higher percentage of prescriptions for GLP-1 medications, with at least 78% of Wegovy prescriptions and 76% of Zepbound prescriptions being for female patients from January to March [6]. - Men are generally less inclined to seek medical help for weight management, often relying on dietary and exercise changes instead [6][7]. - Cultural expectations contribute to the perception that men do not need to be as concerned about obesity, leading to a disparity in the use of weight loss medications [7]. Group 2: Interest in Broader Health Benefits - Men have shown significant interest in the cardiovascular and other health benefits of GLP-1 medications, with Wegovy recently approved for reducing heart disease risk and Zepbound expected to be approved for treating sleep apnea [8]. - The potential for these medications to address multiple health issues may shift the gender balance in their usage, as men begin to see them as more than just weight loss solutions [8]. Group 3: Celebrity Influence - High-profile figures like Boris Johnson and Elon Musk have publicly shared their positive experiences with GLP-1 medications, which may influence public perception and acceptance among men [9][13]. - Johnson noted a significant decrease in appetite and food intake after starting Wegovy, while Musk reported losing 30 pounds with the help of the drug [11][13]. Group 4: Mechanism of Action - GLP-1 medications like semaglutide work by stimulating hormone production that signals satiety to the brain, effectively reducing appetite [10].

Key Takeaways IQVIA beat Q4 earnings and revenue estimates, delivering 9.6% EPS growth and 10.3% Y/Y revenue rise.IQV posted segment gains: R&D and Technology & Analytics grew about 10%, while Contract Sales surged 18.6%.IQVIA guided 2026 revenues at $17.15-$17.35B and reported $2B cash with $561M in Q4 free cash flow.IQVIA Holdings Analytics Inc. (IQV) has reported impressive fourth-quarter 2025 results, wherein earnings and revenues beat the Zacks Consensus Estimate.Adjusted earnings were $3.42 per share, ...

IQVIA (NYSE:IQV) Q4 2025 Earnings call February 05, 2026 09:00 AM ET Company ParticipantsAri Bousbib - CEODavid Windley - Managing Director and Founding memberKerri Joseph - Senior VP of Investor Relations and TreasuryMike Fedock - VP, Financial Planning and AnalysisRon Bruehlman - EVP and CFOShlomo Rosenbaum - Managing Director in the Business Services SectorConference Call ParticipantsElizabeth Anderson - Senior Managing Director and Healthcare Services Equity Research AnalystEric Coldwell - Senior Resear ...

Financial Data and Key Metrics Changes - Full-year revenue growth of 6% and adjusted diluted earnings per share growth of 7% were reported, with free cash flow of $2.1 billion, representing about 100% of adjusted net income [5][21] - Fourth quarter revenue was $4,364 million, up 10.3% on a reported basis and 8.1% at constant currency, with adjusted EBITDA increasing by 5% year-over-year [21][23] - Full-year revenue reached $16.31 billion, up 5.9% reported and 4.8% at constant currency [22] Business Line Data and Key Metrics Changes - Technology Analytics Solutions revenue for Q4 was $1,821 million, up 9.8% reported and 7.1% at constant currency [21] - R&D Solutions revenue for Q4 was $2,333 million, up 9.1% reported and 8.2% at constant currency [21] - Contract Sales and Medical Solutions (CSMS) revenue for Q4 was $210 million, increased 18.6% reported and 15.3% at constant currency [21] Market Data and Key Metrics Changes - Net bookings for R&D Solutions totaled over $2.7 billion, growing 7% year-over-year, with a net book-to-bill ratio of 1.18 [10] - Backlog reached a record of $32.7 billion at the end of the quarter, growing 5.3% compared to the prior year [10][24] - Encouragingly, EVP funding was strong in Q4, reaching $33 billion according to Bioworld [11] Company Strategy and Development Direction - The company is simplifying its organization in 2026 to strengthen collaboration and enhance efficiency, aligning teams with the evolving operating model [15] - A strategic collaboration with Amazon Web Services was announced to accelerate digital transformation in the industry [11] - The company is focusing on AI-driven innovations and has deployed over 150 AI agents across various use cases [38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand environment stabilizing, with improved customer trends and solid execution from sales teams [5][10] - The company anticipates revenue for 2026 to be between $17.15 billion and $17.35 billion, with adjusted EBITDA guidance of $3.975 billion to $4.025 billion [26][27] - Management emphasized that AI is viewed as an enabling technology rather than a threat, enhancing productivity and efficiency [41][62] Other Important Information - The company was recognized by Everest Group for AI leadership, being the only clinical research organization to receive the number one ranking for generative AI leadership in life sciences [12] - The last earnings call for CFO Ron Bruehlman was noted, who will transition to a senior advisory role [17][18] Q&A Session Summary Question: Concerns about AI disrupting established businesses - Management clarified that AI is seen as an opportunity rather than a challenge, emphasizing the proprietary data and domain expertise that differentiate the company [32][34][41] Question: Value and driver of the Cedar Gate acquisition - The acquisition is expected to enhance patient outcomes and provide analytics to payers, with projected revenue of about $140 million in 2025 [46][48] Question: Impact of AI on trial efficiency and demand for services - Management stated that AI will improve trial efficiency but does not foresee a reduction in the number of trials conducted by large pharma [70][72] Question: Margin trajectory and pass-through growth - Management indicated that pass-through growth was a significant driver of gross margin, with expectations for flat overall EBITDA margins in the upcoming year [76][84]

IQVIA (NYSE:IQV) Q4 2025 Earnings call February 05, 2026 09:00 AM ET Speaker7Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the IQVIA Fourth Quarter 2025 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would ...

其提供临床试验服务的研发解决方案部门，四季度营收达23.3 亿美元，超过预期的22.9 亿美元。 当前，合同研究与数据分析企业正面临持续挑战，部分市场中生物技术领域融资趋于谨慎，决策周期也 进一步拉长。 据路孚特（LSEG）数据显示，IQVIA 预计 2026 年调整后每股收益区间为12.55 至 12.85 美元，远低于 分析师平均预期的12.95 美元。 来源：环球市场播报 IQVIA 同时预测，2026 年全年营收区间为171.5 亿至 173.5 亿美元，高于分析师预期的170.7 亿美元。 医疗数据与临床研究服务商 IQVIA 控股周四发布2026 年盈利预测，受利息支出攀升拖累，其年度调整 后利润不及华尔街预期。尽管如此，公司四季度强劲业绩仍凸显制药客户需求持续改善。 在截至 12 月 31 日的四季度，IQVIA 实现调整后每股收益 3.42 美元，营收43.6 亿美元，分别超出分析 师预期的3.40 美元和42.4 亿美元。 公司表示，该预测包含两部分影响：一是 2025 年完成的融资活动带来的利息支出增加，二是 2026 年预 期再融资将产生的近8000 万美元利息成本。 行业同行赛默飞世尔 ...

分组1 - IQVIA Holdings reported quarterly earnings of $3.42 per share, exceeding the Zacks Consensus Estimate of $3.4 per share, and showing an increase from $3.12 per share a year ago, representing an earnings surprise of +0.50% [1] - The company achieved revenues of $4.36 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.83%, and up from $3.96 billion in the same quarter last year [2] - IQVIA has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has underperformed the market, losing about 10.2% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $2.95 on revenues of $4.04 billion, and for the current fiscal year, it is $12.93 on revenues of $17.03 billion [7] 分组3 - The Medical - Instruments industry, to which IQVIA belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for IQVIA was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]

Healthcare data and clinical research provider IQVIA Holdings on Thursday forecast annual profit below Wall Street expectations, weighed down by higher interest costs, even as strong fourth-quarter re... ...

Q4 2025 Earnings Call February 5, 2026 © 2026. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries. IQVIA Template (V4.0.0) 100% 50% 75% 25% Bright Blue Indigo Bright Teal Bright Green Emerald 5% Charcoal Red Legal 2 IQVIA Template (V2.1.0) 100% 50% 75% 25% This presentation should be viewed in conjunction with IQVIA's Q4 2025 earnings call Safe Harbor Statement for Forward-Looking Statements This presentation contains "fo ...

Exhibit 99.1 IQVIA Reports Fourth-Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance RESEARCH TRIANGLE PARK, N.C. – February 5, 2026 – IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended December 31, 2025. "IQVIA closed 2025 with strong performance across all segments," said Ari Bousbib, chairman ...